세계의 항생제 내성 시장 - 치료제 : 병원체별, 치료 유형별 : 상황 분석, 주요 투자가 가이드 첨부(2025-2029년)

Antibiotic Resistance Markets - Therapeutics. By Pathogen and Therapy Type. With Situation Analysis, Executive and Investor Guides. 2025 to 2029

US $ 6,995 ￦ 10,099,000

PDF (Single User License)

PDF 보고서를 1명(One device)만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,495 ￦ 15,152,000

PDF (Five User License)

PDF 보고서를 동일 사업장의 5명(Five devices)까지 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 13,995 ￦ 20,205,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

항생제 내성은 현재의 항생제 의약품에 내성을 가지는 신종의 감염증과 「슈퍼 버그」를 낳고 있습니다.

이 보고서는 세계 항생제 내성 시장에 대해 조사했으며, 시장 개요와 함께 병원체별, 치료 유형별 동향 및 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 시장 가이드

제2장 소개와 시장 정의

• 항생제 내성
• 기회의 정의
• 조사 방법
• 미국 항생제 시장 - 전망

제3장 시장 개요

• 시장 진출기업 - 역할과 영향
• 항생제 내성의 이해
• 새로운 항생제와 기술에 변화하는 길
• AMR에서 진단의 중요한 역할

제4장 AMR 시장 기회

• AMR의 주요 대규모 시장 기회
• 치료 기술 개발의 기회

제5장 항생제 내성의 최근 동향

제6장 주요 기업과 그 기술

• Melinta Therapeutics
• Arsanis
• Phage Technologies SA
• Westway Health
• Tetraphase Pharmaceuticals
• BioVersys GmbH
• Nabriva Therapeutics
• Macrolide Pharmaceuticals
• Nemesis Bioscience
• C3J Therapeutics, Inc.
• EpiBiome
• discuva
• SmartPhage
• AmpliPhi Biosciences
• Pherecydes Pharma
• Micreos
• Procarta Biosystems
• Lumavita
• Madam Therapeutics
• Priaxon
• Biolytx Pharmaceuticals
• AntibioTx
• Xellia Pharmaceutials
• Paratek Pharmaceuticals
• Synereca Pharmaceuticals
• Allecra Therapeutics
• Fixed Phage
• Enanta Pharmaceuticals, Inc.
• Demuris
• Prommune
• Biosergen
• Innovation Pharmaceuticals
• Aviragen Therapeutics
• Achillion Pharmaceuticals
• ImmunNovative Developments, SL
• Achaogen, Inc
• SelectX Pharmaceuticals, Inc.
• TaiGen Biotechnology Co., Ltd.
• Theravance Biopharma
• Abbvie
• KYORIN Pharmaceutical Co.,Ltd.
• Iterum Therapeutics Limited
• Forge Therapeutics
• Alopexx Vaccine LLC
• Integrated Biotherapeutics
• Hennepin Life Sciences
• Fedora Pharmaceuticals Inc.
• Contrafect Corporation
• Basilea Pharmaceutica Ltd.
• AiCuris
• RedHill Biopharma
• Redx Pharma Plc/Redx Anti Infectives Ltd.
• ABAC Therapeutics
• Alaxia SAS
• Antabio SAS
• Auspherix Ltd
• BioFilm Pharma
• Centauri Therapeutics Ltd
• Combioxin SA
• Da Volterra
• Debiopharm International SA
• Deinobiotics/Deinove
• Destiny Pharma plc
• Eligo Bioscience
• Helperby Therapeutics Ltd
• Karveel Pharmaceuticals
• MaaT Pharma
• Motif BioSciences, Inc/Motif Bio PLC
• Mutabilis SAS
• Neem Biotech Ltd
• Northern Antibiotics Oy(Ltd)
• Nosopharm
• NovaBiotics Ltd
• Phico Therapeutics Ltd
• Polyphor Ltd
• QureTech Bio AB
• SetLance srl
• Ultupharma AB
• Vaxdyn
• Vibiosphen
• Bioaster
• Vivexia
• KBP Biosciences
• Absynth Biologics
• Spero Therapeutics
• Merck
• Symphogen
• Warp Drive Bio
• Johnson & Johnson(Janssen)
• Pfizer
• Allergan
• GlaxoSmithKline
• Novartis
• Gilead Sciences
• AstraZeneca
• Sanofi
• Shionogi Inc.
• Cipla
• DSM Sinochem Pharmaceuticals
• Wockhardt Ltd.
• VenatoRx Pharmaceuticals
• MicuRx
• Entasis Therapeutics
• Merlion Pharmaceuticals
• Aridis Pharmaceuticals Inc.
• 치료제 경쟁 - 기업의 연구 분야 개요

제7장 세계 시장 규모

제8장 병원체별 시장 규모

제9장 기술별 시장 규모

제10장 AMR의 미래

제11장 부록

JHS

영문 목차

영문목차

Report Overview:

Antimicrobial Resistance is creating new kinds of infections and "superbugs" that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. We have identified the 6 Key Large Opportunities in this space and developed market forecasts. We have looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play. This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. And we summarize what technologies they are using.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

• 1.1. Strategic Situation Analysis
• 1.2. Guide for Executives and Business Development Staff
• 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

• 2.1. Antimicrobial Resistance
• 2.2. Defining the Opportunity
  • 2.2.1. Revenue Market Size
• 2.3. Methodology
  • 2.3.1. Methodology
  • 2.3.2. Sources
  • 2.3.3. Authors
• 2.4. U.S. Antibiotic Markets - Perspective
  • 2.4.1. U.S. Outpatient Use of Antibiotics
  • 2.4.2. U.S. Pharmaceutical Spending

3. Overview of a Dynamic Market

• 3.1. Market Players - Roles & Impacts
  • 3.1.1. Drug manufacturers - Larger/pharmaceutical
  • 3.1.2. Drug manufacturers - Generic
  • 3.1.3. Contract Research and Manufacturing
  • 3.1.4. In Vitro Diagnostics Industry
  • 3.1.5. Drug Marketing Companies
  • 3.1.6. Biotechnology Companies
  • 3.1.7. Regulatory Bodies
• 3.2. Understanding Antimicrobial Resistance
  • 3.2.1. What is Antimicrobial Resistance (AMR)
  • 3.2.2. Bacteria and Other Microbes
  • 3.2.3. The History of Antibiotics
  • 3.2.4. The Role of Animal Husbandry
  • 3.2.5. The Implications of Horizontal Transfer
  • 3.2.6. The Threat of AMR
• 3.3. The Changing Road to New Antibiotics & Technologies
• 3.4. The Key Role of Diagnostics in AMR

4. The Market Opportunity of AMR

• 4.1. The Key Large Market Opportunities in AMR
  • 4.1.1. Streptococcus Pneumoniae (DRSP)
  • 4.1.2. Campylobacter (DRC)
  • 4.1.3. Clostridium Difficile (CD)
  • 4.1.4. Staphylococcus aureus (MRSA)
  • 4.1.5. Neisseria gonorrhoeae (DRNG)
  • 4.1.6. Salmonella (DRNTS)
• 4.2. Therapeutic Technology Development Opportunities
  • 4.2.1. Using Viruses Against Bacteria
  • 4.2.2. Hydrolytic Enzymes Join the Fight
  • 4.2.3. Antibodies
  • 4.2.4. Vaccines
  • 4.2.5. Probiotic Technology
  • 4.2.6. Peptides vs. Pathogens
  • 4.2.7. Mining Obsolete Science
  • 4.2.8. CRISPR Antibiotics

5. Antibiotic Resistance Recent Developments

• 5.1.1. Recent Developments - Importance and How to Use This Section
• 5.1.2. Importance of These Developments
• 5.1.3. How to Use This Section
• 5.2. Drug-free method to combat AMR
• 5.3. Superbug linked to a common antibiotic
• 5.4. Building evidence for the use of bacteriophages against AMR
• 5.5. Phage Therapies to Crush Antimicrobial Resistance
• 5.6. Bacteriophage May Combat AMR
• 5.7. Shionogi to Acquire Qpex Biopharma
• 5.8. Adaptive Phage Therapeutics to Fight Antibiotic Resistance
• 5.9. Smartbax to create next-generation antibiotics
• 5.10. Startup Solu raises Euro-1M to combat AMR
• 5.11. Akthelia Pharma and University of Iceland to Combat AMR
• 5.12. WHO warns of too few new Antibiotics
• 5.13. Bactobio Raises Pound-6 Million To Discover Novel Antimicrobials
• 5.14. AMR triggers race to develop phages
• 5.15. AMR Pandemic Overlooked
• 5.16. New resistance-busting antibiotic combination
• 5.17. CDC Awards $22M to Combat Antimicrobial Resistance
• 5.18. Antibiotic resistance outwitted by supercomputers
• 5.19. STIs Reach Record Highs
• 5.20. New research using nanoparticles to bolster waning antibiotics
• 5.21. OpGen Receives FDA Clearance for AMR Panel
• 5.22. CDC Updates STI Diagnosis, Treatment Guidelines
• 5.23. Positive associations between AM use in animals and AMR in humans
• 5.24. PEW Antibiotic Pipeline Findings

6. Key Biotechnology Companies and Their Technology

• 6.1. Melinta Therapeutics
• 6.2. Arsanis
• 6.3. Phage Technologies S.A
• 6.4. Westway Health
• 6.5. Tetraphase Pharmaceuticals
• 6.6. BioVersys GmbH
• 6.7. Nabriva Therapeutics
• 6.8. Macrolide Pharmaceuticals
• 6.9. Nemesis Bioscience
• 6.10. C3J Therapeutics, Inc.
• 6.11. EpiBiome
• 6.12. discuva
• 6.13. SmartPhage
• 6.14. AmpliPhi Biosciences
• 6.15. Pherecydes Pharma
• 6.16. Micreos
• 6.17. Procarta Biosystems
• 6.18. Lumavita
• 6.19. Madam Therapeutics
• 6.20. Priaxon
• 6.21. Biolytx Pharmaceuticals
• 6.22. AntibioTx
• 6.23. Xellia Pharmaceutials
• 6.24. Paratek Pharmaceuticals
• 6.25. Synereca Pharmaceuticals
• 6.26. Allecra Therapeutics
• 6.27. Fixed Phage
• 6.28. Enanta Pharmaceuticals, Inc.
• 6.29. Demuris
• 6.30. Prommune
• 6.31. Biosergen
• 6.32. Innovation Pharmaceuticals
• 6.33. Aviragen Therapeutics
• 6.34. Achillion Pharmaceuticals
• 6.35. ImmunNovative Developments, S.L.
• 6.36. Achaogen, Inc
• 6.37. SelectX Pharmaceuticals, Inc.
• 6.38. TaiGen Biotechnology Co., Ltd.
• 6.39. Theravance Biopharma
• 6.40. Abbvie
• 6.41. KYORIN Pharmaceutical Co.,Ltd.
• 6.42. Iterum Therapeutics Limited
• 6.43. Forge Therapeutics
• 6.44. Alopexx Vaccine LLC
• 6.45. Integrated Biotherapeutics
• 6.46. Hennepin Life Sciences
• 6.47. Fedora Pharmaceuticals Inc.
• 6.48. Contrafect Corporation
• 6.49. Basilea Pharmaceutica Ltd.
• 6.50. AiCuris
• 6.51. RedHill Biopharma
• 6.52. Redx Pharma Plc/ Redx Anti Infectives Ltd.
• 6.53. ABAC Therapeutics
• 6.54. Alaxia SAS
• 6.55. Antabio S.A.S
• 6.56. Auspherix Ltd
• 6.57. BioFilm Pharma
• 6.58. Centauri Therapeutics Ltd
• 6.59. Combioxin SA
• 6.60. Da Volterra
• 6.61. Debiopharm International SA
• 6.62. Deinobiotics/Deinove
• 6.63. Destiny Pharma plc
• 6.64. Eligo Bioscience
• 6.65. Helperby Therapeutics Ltd
• 6.66. Karveel Pharmaceuticals
• 6.67. MaaT Pharma
• 6.68. Motif BioSciences, Inc / Motif Bio PLC
• 6.69. Mutabilis SAS
• 6.70. Neem Biotech Ltd
• 6.71. Northern Antibiotics Oy (Ltd)
• 6.72. Nosopharm
• 6.73. NovaBiotics Ltd
• 6.74. Phico Therapeutics Ltd
• 6.75. Polyphor Ltd
• 6.76. QureTech Bio AB
• 6.77. SetLance srl
• 6.78. Ultupharma AB
• 6.79. Vaxdyn
• 6.80. Vibiosphen
• 6.81. Bioaster
• 6.82. Vivexia
• 6.83. KBP Biosciences
• 6.84. Absynth Biologics
• 6.85. Spero Therapeutics
• 6.86. Merck
• 6.87. Symphogen
• 6.88. Warp Drive Bio
• 6.89. Johnson & Johnson (Janssen)
• 6.90. Pfizer
• 6.91. Allergan
• 6.92. GlaxoSmithKline
• 6.93. Novartis
• 6.94. Gilead Sciences
• 6.95. AstraZeneca
• 6.96. Sanofi
• 6.97. Shionogi Inc.
• 6.98. Cipla
• 6.99. DSM Sinochem Pharmaceuticals
• 6.100. Wockhardt Ltd.
• 6.101. VenatoRx Pharmaceuticals
• 6.102. MicuRx
• 6.103. Entasis Therapeutics
• 6.104. Merlion Pharmaceuticals
• 6.105. Aridis Pharmaceuticals Inc.
• 6.106. The Therapeutics Race - Summary of Companies Research Areas

7. Global Market Size

• 7.1. Global Market by Country
• 7.2. Global Market by Pathogen
• 7.3. Global Market by Technology

8. Market Sizes by Pathogen

• 8.1. DRSP Market
• 8.2. DRC Market
• 8.3. CD Market
• 8.4. MRSA Market
• 8.5. DRNG Market
• 8.6. DRNTS Market
• 8.7. Other Pathogen Market

9. Market Sizes by Technology

• 9.1. Antibiotics Market
• 9.2. Phage Market
• 9.3. Pep/Lys Market
• 9.4. Antibodies Market
• 9.5. Vaccine Market
• 9.6. Other Technology Market

10. The Future of AMR

11. Appendices

• 11.1. United States Medicare System: Top Selling Drugs

관련자료